A. Clinton White

Prof. A. Clinton White

UT Medical Branch at Galveston, Galveston, TX, USA
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
WCWilliam Checkley
William Checkley
AWA. Clinton White
A. Clinton White
DJDevan Jaganath
Devan Jaganath
MAMichael J Arrowood
Michael J Arrowood
RCRachel M Chalmers
Rachel M Chalmers
EHEric R Houpt
Eric R Houpt

24 July 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
OBO. H. Del Brutto
O. H. Del Brutto
VRV. Rajshekhar
V. Rajshekhar
AWA. Clinton White
A. Clinton White
VTV. C. W. Tsang
V. C. W. Tsang
TNT. E. Nash
T. E. Nash
HGH.H. García
H.H. García
Neurocysticercosis is the most common helminthic infection of the CNS but its diagnosis remains difficult. Clinical manifestations are nonspecific, most neuroimaging findings are not pathognomonic, and some serologic tests have low sensitivity and specificity. The authors provide diagnostic criteria for neurocysticercosis based on objective clinical, imaging, immunologic, and epidemiologic data. These include four categories of criteria stratified on the basis of their diagnostic strength, including the following: 1) absolute—histologic demonstration of the parasite from biopsy of a brain or spinal cord lesion, cystic lesions showing the scolex on CT or MRI, and direct visualization of subretinal parasites by funduscopic examination; 2) major—lesions highly suggestive of neurocysticercosis on neuroimaging studies, positive serum enzyme-linked immunoelectrotransfer blot for the detection of anticysticercal antibodies, resolution of intracranial cystic lesions after therapy with albendazole or praziquantel, and spontaneous resolution of small single enhancing lesions; 3) minor—lesions compatible with neurocysticercosis on neuroimaging studies, clinical manifestations suggestive of neurocysticercosis, positive CSF enzyme-linked immunosorbent assay for detection of anticysticercal antibodies or cysticercal antigens, and cysticercosis outside the CNS; and 4) epidemiologic—evidence of a household contact with Taenia solium infection, individuals coming from or living in an area where cysticercosis is endemic, and history of frequent travel to disease-endemic areas. Interpretation of these criteria permits two degrees of diagnostic certainty: 1) definitive diagnosis, in patients who have one absolute criterion or in those who have two major plus one minor and one epidemiologic criterion; and 2) probable diagnosis, in patients who have one major plus two minor criteria, in those who have one major plus one minor and one epidemiologic criterion, and in those who have three minor plus one epidemiologic criterion.

4 March 2005 in AIDS
Verified
Journal Article
Closed access
SSSamuel A Shelburne
Samuel A Shelburne
FVFehmida Visnegarwala
Fehmida Visnegarwala
JDJorge Darcourt
Jorge Darcourt
EGEdward A Graviss
Edward A Graviss
TGThomas Peter Giordano
Thomas Peter Giordano
RHRichard J Hamill
Richard J Hamill
There is little systematic information regarding the immune reconstitution inflammatory syndrome (IRIS). To determine the incidence, risk factors, and long-term outcome of IRIS in HIV-infected patients receiving highly active antiretroviral therapy (HAART) who were coinfected with one of three common opportunistic pathogens. A retrospective cohort identified through a city-wide prospective surveillance program. A retrospective chart review was performed for 180 HIV-infected patients who received HAART and were coinfected with Mycobacterium tuberculosis, Mycobacterium avium complex, or Cryptococcus neoformans between 1997 and 2000. Medical records were reviewed for baseline demographics, receipt and type of HAART, response to antiretroviral therapy, development of IRIS, and long-term outcome. In this cohort, 31.7% of patients who received HAART developed IRIS. Patients with IRIS were more likely to have initiated HAART nearer to the time of diagnosis of their opportunistic infection (P < 0.001), to have been antiretroviral naive at time of diagnosis of their opportunistic infection (P < 0.001), and to have a more rapid initial fall in HIV-1 RNA level in response to HAART (P < 0.001). IRIS is common among HIV-infected persons coinfected with M. tuberculosis, M. avium complex, or C. neoformans. Antiretroviral drug-naive patients who start HAART in close proximity to the diagnosis of an opportunistic infection and have a rapid decline in HIV-1 RNA level should be monitored for development of this disorder.

1 June 2007 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
TGThomas Peter Giordano
Thomas Peter Giordano
AGAllen L. Gifford
Allen L. Gifford
AWA. Clinton White
A. Clinton White
MAMaria E. Suarez Almazor
Maria E. Suarez Almazor
LRLinda Rabeneck
Linda Rabeneck
RMRobert O. Morgan
Robert O. Morgan
Background. Patients with human immunodeficiency virus (HIV) infection need lifelong medical care, but many do not remain in care. The effect of poor

1 October 2002 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
HGHector H. García
Hector H. García
CECarlton A. W. Evans
Carlton A. W. Evans
TNTheodore E. Nash
Theodore E. Nash
OTOsvaldo M. Takayanagui
Osvaldo M. Takayanagui
AWA. Clinton White
A. Clinton White
OBOscar H. Del Brutto
Oscar H. Del Brutto
SUMMARY: Taenia solium neurocysticercosis is a common cause of epileptic seizures and other neurological morbidity in most developing countries. It is also an increasingly common diagnosis in industrialized countries because of immigration from areas where it is endemic. Its clinical manifestations are highly variable and depend on the number, stage, and size of the lesions and the host's immune response. In part due to this variability, major discrepancies exist in the treatment of neurocysticercosis. A panel of experts in taeniasis/cysticercosis discussed the evidence on treatment of neurocysticercosis for each clinical presentation, and we present the panel's consensus and areas of disagreement. Overall, four general recommendations were made: (i) individualize therapeutic decisions, including whether to use antiparasitic drugs, based on the number, location, and viability of the parasites within the nervous system; (ii) actively manage growing cysticerci either with antiparasitic drugs or surgical excision; (iii) prioritize the management of intracranial hypertension secondary to neurocysticercosis before considering any other form of therapy; and (iv) manage seizures as done for seizures due to other causes of secondary seizures (remote symptomatic seizures) because they are due to an organic focus that has been present for a long time.

1 February 2000 in Annual Review of Medicine
Verified
Journal Article
Closed access
AWA. Clinton White
A. Clinton White
▪ Abstract Neurocysticercosis is now recognized as a common cause of neurologic disease in developing countries and the United States. The pathogenesis and clinical manifestations vary with the site of infection and accompanying host response. Inactive infection should be treated symptomatically. Active parenchymal infection results from an inflammatory reaction to the degenerating cysticercus and will also respond to symptomatic treatment. Controlled trials have not demonstrated a clinical benefit for antiparasitic drugs. Ventricular neurocysticercosis often causes obstructive hydrocephalus. Surgical intervention, especially cerebrospinal fluid diversion, is the key to management of hydrocephalus. Shunt failure may be less frequent when patients are treated with prednisone and/or antiparasitic drugs. Subarachnoid cysticercosis is associated with arachnoiditis. The arachnoiditis may result in meningitis, vasculitis with stroke, or hydrocephalus. Patients should be treated with corticosteroids, antiparasitic drugs, and shunting if hydrocephalus is present.